Omicron, surely that’s enough

What have the scientific, pharmaceutical, and medical communities done to stifle SARS-CoV-2 infections? There are currently 18 advanced trials of different vaccines, 64 possible new treatments, and 23 potential or approved anti-viral drugs.

The mRNA vaccines from Pfizer and Moderna provide robust protection. (The mRNA technology is being expanded to HIV, malaria, and other diseases for which conventional vaccines have failed.) mRNA vaccines are expensive and need to be shipped frozen. Lower income countries require an effective vaccine that is inexpensive, survives at higher temperature and can be made locally.  Corbevax, created at Baylor College of Medicine, fits these criteria and is currently being made in hundreds of millions of doses in India. Other vaccines (Novovax) produce antibodies to viral proteins in addition to the Spike protein. The Novovax vaccine contains no genetic material.

Beyond vaccines there are 64 new treatments in development that block or slow infection or some of its consequences, like inflammation. Inflammation makes blood vessels leaky; defensive cells, which rush to the site of infection, squeeze out of the circulation, and infiltrate the lungs. They fill air sacs with dead neutrophils, eosinophils, and fluid, making the patient struggle to breathe.  In addition to the inflammatory reaction, when these cells die they release digestive enzymes that can do terrible damage to the lungs or other infected tissues. The use of steroids to inhibit inflammation was a critical early discovery. According to a review I read recently, it is still the best early intervention. Most viruses have means to inhibit a host’s immune system:  some inhibit interferon synthesis, a critical mobilizer of the immune response; SARS-CoV-2 inhibits the production of Natural Killer cells, which recognize infected lung cells and kill them. The more we know about these mechanisms the better off we will be.

There are currently 23 antivirals approved or in testing, including Merck’s Molnupiravir and Pfizer’s Paxlovid, but others have Emergency Use Authorizations as well. Paxlovid, if taken within 5 days of the onset of symptoms, blocks disease progression and keeps 90% of patients from hospitalization.  As a result, our hospitals are able to function, saving money, reducing misery and increasing morale.  Vaccinated and boosted people usually have a short illness unless they have other complications and may not need these therapeutics. But for those who do, or are unvaccinated the drugs are becoming available in pharmacies.

My friend, Jonathan Sanoff, keeps track of these things. He told me about a site called the Therapeutics Locator, which The Assistant Secretary for Preparedness and Response at The Department of Health and Human Services and her staff have prepared. The Assistant Secretary is Rear Admiral Rachel L. Levine, MD. The site tells potential patients where to find these drugs, whether they are in Puerto Rico or Alaska. For skeptics, the site also includes the number of doses on hand at each site and the total made so far, as well as information on each drug. As new therapies come online, they will appear on the Therapeutics Locator. There are currently seven drugs and monoclonal antibodies on the site. The Asst Secretary and her staff do not get much credit, but they should. See: www.covid-19-therapeutics-locator-dhhs.hub.arcgis.com/.

It is important to have many anti-viral drugs, and I was surprised to learn that 23 are still in late clinicals trials. We learned from HIV therapy that an RNA virus can develop resistance to a single drug but cannot evolve resistance to three drugs and is why the number 23 is a pleasant surprise. An even better surprise is, some of these drugs inhibit other RNA viruses, including Zika and Ebola.

Nothing in science or medicine must work, no matter how clever the idea. We should not be surprised that 26 vaccines failed, 92 treatments did not pass muster, and 54 antivirals did not inhibit SARS-CoV-2.  These results on therapies in the development pipeline have been collected by Heidi Ledford, one of Nature Magazine’s senior reporters (Nature, March 3, 2022). I am grateful to her. In that context, the March 11 issue of Science, the flagship publication of the American Academy of Sciences, contains a detailed comparison and analysis of these treatments and ideas on what we need to prepare for the next epidemic. Pandemics are too large a subject to cover everything — we have left out the value of logistics and convincing people to take vaccines, not to mention long Covid, but people are studying these challenges. The combination of basic science, private industry, and public health services have done well, although praise sounds hollow when millions have died.

What to do? Get vaccinated and boosted. When new boosters designed to attack SARS-CoV-2 or its variants appear, get those too. Even with the vaccine, you may get mild disease, but the name of the game is to prevent progress to serious disease and hospitalization. The new drugs offer reassurance. In places where the virus and infection are in decline, it is time to resume normal life.  Or at least that is my plan.

 

Richard Kessin is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. Reach him at Richard.Kessin@gmail.com. His website contains more information: RichardKessin.com.

 

 

       

             

 

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

‘Vulnerable Earth’ opens at the Tremaine Gallery

Tremaine Gallery exhibit ‘Vulnerable Earth’ explores climate change in the High Arctic.

Photo by Greg Lock

“Vulnerable Earth,” on view through June 14 at the Tremaine Gallery at Hotchkiss, brings together artists who have traveled to one of the most remote regions on Earth and returned with work shaped by first-hand experience of a fragile, rapidly shifting planet, inviting viewers to sit with the tension between awe and loss, beauty and vulnerability.

Curated by Greg Lock, director of the Photography, Film and Related Media program at The Hotchkiss School, the exhibition centers on participants in The Arctic Circle, an expeditionary residency that sends artists and scientists into the High Arctic aboard a research vessel twice a year. The result is a show documenting their lived experience and what it means to stand in a place where climate change is not theoretical but visible, immediate and accelerating.

Keep ReadingShow less
Beyond Hammertown: Joan Osofsky designs what comes next

Joan Osofsky and Sharon Marston

Provided

Joan Osofsky is closing the doors on Hammertown, one of the region’s most beloved home furnishings and lifestyle destinations, after 40 years, but she is not calling it an ending.

“I put my baby to bed,” she said, describing the decision with clarity and calm. “It felt like the right time.”

Keep ReadingShow less
A celebratory season of American classics and new works at Barrington Stage Company
Playwright Keelay Gipson’s “Estate Sale” will have its world premier this summer at Barrington Stage Company.
Provided

Amid the many cultural attractions in the region, the Barrington Stage Company in Pittsfield, Massachusetts, stands out for its award-winning productions and comprehensive educational and community-based programming. The theater’s 2026 season is one of its most ambitious; it includes two Pulitzer Prize-winning modern classics, one of the greatest theatrical farces ever written, and new works that speak directly to who we are right now as a society.

“Our 2026 season is a celebration of extraordinary storytelling in all its forms — timeless, uproarious and boldly new,” said Artistic Director Alan Paul. “This season features works that have shaped the American theater, as well as world premieres that reflect the company’s deep commitment to developing new voices and new stories. Together, these productions embody what BSC does best: entertain, challenge and connect our audiences through theater that feels both essential and alive.”

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Hotchkiss Film Festival celebrates 15th year of emerging filmmakers

Student festival directors Trey Ramirez (at the mic) and Leon Li introducing the Hotchkiss Film Festival.

Brian Gersten

The 15th annual Hotchkiss Film Festival took place Saturday, April 25, marking a milestone year for a student-driven event that continues to grow in ambition, reach and artistic scope. The festival was founded in 2012 by Hotchkiss alumnus and Emmy-nominated filmmaker Brian Ryu. Ryu served as a festival juror for this year’s installment, which showcased a selection of emerging filmmakers from around the region. The audience was treated to 17 films spanning drama, horror, comedy, documentary and experimental forms — each reflecting a distinct voice and perspective.

This year’s program was curated by student festival directors Trey Ramirez and Leon Li, working alongside faculty adviser Ann Villano. With more than 52 submissions received, the selection process was both rigorous and rewarding. The final lineup included six films from Hotchkiss students.

Keep ReadingShow less
Artist Maira Kalman curates ‘Shaker Outpost’ in Chatham

The Laundry Room, a painting by Maira Kalman from the exhibition “Shaker Outpost: Design, Commerce, and Culture” at the Shaker Museum’s pop-up space in Chatham.

Photo by Maira Kalman; Courtesy of the artist and Mary Ryan Gallery, New York

With “Shaker Outpost: Design, Commerce, and Culture,” opening May 2, the Shaker Museum in Chatham invites artist and writer Maira Kalman to pair her own new paintings with objects from the museum’s vast holdings, and, in the process, reintroduce the Shakers not as relic, but as a living argument for clarity, usefulness and grace.

Born in Tel Aviv, Maira Kalman is a New York–based artist and writer known for her illustrated books, wide-ranging collaborations and distinctive work spanning publishing, design and fine art.

Keep ReadingShow less

Ticking Tent spring market returns

Ticking Tent spring market returns

The Ticking Tent Spring Market returns to Spring Hill Vineyards in New Preston on May 2.

Jennifer Almquist

The Ticking Tent Spring Market returns to New Preston Saturday, May 2, bringing more than 60 antiques dealers, artisans and design brands to Spring Hill Vineyards for a one-day, brocante-style shopping event from 9 a.m. to 4 p.m.

Co-founders Christina Juarez and Benjamin Reynaert invite visitors to the outdoor market at 292 Bee Brook Road, where curated vendors will offer home goods, fashion, tabletop and collectible design. Guests can browse while enjoying Spring Hill Vineyards’ wines and seasonal fare.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.